Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.
about
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsGuide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsAnalysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyOptimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.Mathematical Modelling and Prediction of the Effect of Chemotherapy on Cancer Cells.Diagnosis of Lung Cancer by Fractal Analysis of Damaged DNALongitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Considerations for standardizing predictive molecular pathology for cancer prognosis.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Liquid Biopsy in Non-Small Cell Lung Cancer.Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics.Integrating liquid biopsies into the management of cancer.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?Circulating DNA in EGFR-mutated lung cancer.Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry.The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma.Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer.Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.
P2860
Q26769734-75AF210A-F634-4EB7-825D-B494A3FB440AQ26775376-3A7281BB-359E-44C0-8D39-17C00F6AAF99Q26801357-73C0E77C-AE62-45C7-9A81-F08C6A866878Q28077340-63DFC131-5527-4BA9-8918-AA1043C0A64EQ28077570-438FA759-7713-4D50-8518-EC746502E22DQ28079253-7CFF4E2F-1A4A-49BD-BFC3-15A15CAEC362Q28086768-CE755128-2938-4B21-BE82-54473823D46BQ33598423-7BD2F629-F3D0-45D9-91E7-6E9C9F4D519FQ33757134-B7B59571-0C2A-457D-A648-AFC243C3315CQ34515855-EC9BA88E-495E-476E-9386-3643BC927818Q35004426-F0D9E61E-48F0-40DE-BC30-4139DFAF284DQ36002786-22020C9D-D649-4BFF-823E-86C70312B885Q36204319-D5E36F72-61D4-4334-B1B0-DADD422153E4Q36916399-161437EB-70CF-476D-90B1-A45F802A6F09Q37536958-FBE001AE-9CDA-41AA-9947-7D9DB4D2ADCFQ37592893-B9B388A1-3120-4214-BDAB-0832043F1923Q37701499-C8D54412-D655-4CCD-8C08-93302C912912Q38694431-B55CCF74-1919-4F65-80B9-3F2DFA32DACAQ38789496-44D2780A-9D83-470B-9E20-42BF305BCD6EQ38844281-BB47FDBC-DDA8-4077-A43B-0A5350B0E89CQ39076207-A9533306-C209-4E47-BED1-9426B81E4AF4Q39139907-919D1681-F499-4A65-B508-E0019D17E22BQ39157824-F0B7B279-581D-4C9E-9B0B-F3C2D688F55AQ39294398-DDEF5B87-1D43-408C-91D5-209BD6AC8164Q41260159-90D9C5AA-84A5-474A-AF8C-496669F62FE9Q41311492-005DA6AB-32B9-4871-AE95-945584E628E9Q41472736-7B6F89E6-CE5B-4395-9245-3B77C53ACD8DQ41866575-0F23D477-93BC-4B63-982D-ED24318FD8A6Q46917029-B2C6FE5E-6703-48AC-9719-348B8299F4BAQ46984199-7385D29F-7E6E-4051-80AC-ADCA3B753769Q47162466-757A5944-4809-41E4-86FE-234FB10BDED9Q47563363-DF810F9F-C422-41E6-BF16-70B19A05263CQ47642602-7C70C93D-EA99-4E44-B645-59A6DF1245C7Q48524081-BFD9D902-25A1-432F-8144-27E5C3035C14Q49963088-F1255A74-5146-4E58-A978-9BC73136C937Q54979898-F6762F52-E5D5-4DE5-9049-458A7196826DQ55058129-377476BD-BABA-44DA-9275-CB61DC51272FQ55226999-96FB84C3-43E1-40C2-8197-A39F48F77022Q55282794-9AD3CF69-0BFD-481A-8DDF-605232116DA3Q55334265-53C25790-4497-46DE-90EE-A28C2A039C18
P2860
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@ast
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@en
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@nl
type
label
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@ast
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@en
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@nl
prefLabel
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@ast
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@en
Detection of EGFR mutations in ...... by allele-specific PCR assays.
@nl
P2093
P2860
P50
P356
P1433
P1476
Detection of EGFR mutations in ...... by allele-specific PCR assays
@en
P2093
P2860
P2888
P356
10.1186/1471-2407-14-294
P407
P577
2014-04-28T00:00:00Z
P5875
P6179
1011532007